Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517226 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05517226 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT05517226, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.
Interventions
- COMBINATION_PRODUCT Cotadutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05517226
The ClinicalTrials.gov registry entry for NCT05517226 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cotadutide is the first listed.
NCT05517226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05517226 about?
NCT05517226 is a clinical study titled "Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment". This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.
What is the current status of trial NCT05517226?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-09-06. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT05517226?
The interventions under investigation include: Cotadutide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05517226?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.